Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jul 26;16(7):e0255092. doi: 10.1371/journal.pone.0255092

Inhibition of acetic acid-induced colitis in rats by new Pediococcus acidilactici strains, vitamin producers recovered from human gut microbiota

Nahla M Mansour 1,*, Wagiha S Elkalla 2, Yasser M Ragab 3, Mohamed A Ramadan 3
Editor: Mahmoud Abdel Aziz Mabrok4
PMCID: PMC8312973  PMID: 34310635

Abstract

Our aim was to isolate, identify and characterize probiotic bacteria as vitamin producers in particular B2 and B9. 150 human fecal samples were collected and used for isolation of vitamin producers—probiotics. 49 isolates were chosen for screening their genome by PCR for the presence of riboflavin and folic acid genes. As a result, three isolates were selected and their production of the B2 and B9 were confirmed by HPLC. The three isolates were identified on species level by sequencing their 16S rRNA gene which showed 100% identical to strains of Pediococcus acidilactici. Thus, they were named as P. acidilactici WNYM01, P. acidilactici WNYM02, P. acidilactici WNYM03 and submitted to the Genbank database with accession numbers. They met the probiotic criteria by expressing 90–95% survival rate at pH (2.0–9.0) and bile salt up to 2% for 3 h in addition to their antimicrobial activity against gram positive and negative microorganisms. They also showed no hemolytic activity and common pattern for antibiotic susceptibility. Our three strains were tested individually or in mixture in vivo on rat colitis model compared to ulcerative group. The strains were administrated orally to rats in daily dose containing CFU 109 for 14 days then followed by induction of colitis using acetic acid then the oral administration was continued for more four days. The histology results, the anti-inflammatory and anti-oxidative stress biomarkers showed the protective role of the strains compared to the ulcerative group. As a conclusion, we introduce novel three probiotic candidates for pharmaceutical preparations and health applications.

Introduction

Human beings are associated with a huge number of massive varieties of microorganisms termed "microbiota" that live on and in our bodies. Its microbial communities are host specific thus the microbiota habitat the intestinal mucosal surface or even in the gut lumen are known as ‘Gut Microbiota’ [13]. The gut microbiota provides metabolites and molecules which act as fundamental elements in human health and disease.

The vitamins are essential for sustaining the proper functioning of human beings and other organisms. One of them is vitamin B complex which is a family of eight diverse vitamins that support human body for accomplishment energy from food needed for all of the basic growth and life-sustaining processes. Vitamin B deficiency could lead to many complications such as fatigue, anemia, stomach pain, numbness, depression, in addition to respiratory infection [4, 5].

B vitamins could not be synthesized by the mammals and only synthesized by certain plants and microorganisms, thus these vitamins would be supplied through the diet. The variations between the individuals in their diet, daily activity and health status leads to B vitamins deficiencies or over excess. Although, the gut microbiota is now recognized as a potential source of B vitamins however not all gut microorganisms are capable to synthesize the B vitamins. In this work we will focus on two vitamins from the B vitamins family: B2 and B9.

B2 vitamin is known as riboflavin in addition to lactoflavin as it was first isolated from milk [6, 7]. It is a water-soluble vitamin and cannot be stored in the human body thus it needs to be daily intake. B2 vitamin considers the principle growth promoting factor in vitamin B complex; it has anti-inflammatory plus antioxidant effects and defends the oxidant-mediated inflammatory damage in lungs [8] it also stimulates phagocytosis and proliferation of macrophages and neutrophils [9]. Many studies illustrate the mechanism of the anti-inflammatory effects of riboflavin [10, 11] which decrease the production of pro-inflammatory cytokines, tumor necrosis factor-α [TNF-α], and interleukin-6 [IL-6]. In addition, the vitamin has a synergistic effect on the anti-inflammatory action of dexamethasone. Furthermore, it is linked to the generation of reactive oxygen species (ROS) which consider signaling key for the immune cells and inflammation via NADPH oxidase 2 [12].

Vitamin B9 is known as folate and play as a cofactor for, amino acids and DNA synthesis in addition to other metabolic reactions also it is essential for red blood cells and supports the maintenance of immunologic homeostasis. WHO/FAO [13] recommends a daily vitamin B9 intake of 400 μg for adults as its deficiency cause megaloblastic anemia [14]; the reduction of the Treg cells which control the immune responses [15]; increased susceptibility to intestinal inflammation [16] and some psychological illnesses [17]. Thus, the appropriate intake of folate is crucial for normal development, growth and health. The availability of dietary vitamin B2 and B9 in addition to the diverse microbiota to metabolize them may have impact on activation the immune system specifically the mucosal-associated invariant T (MAIT) cells in the intestine [18].

Changes in gut microbiota composition have associated with many diseases including immunity disorder, vitamins deficiency, inflammation and cancer. Strategies to improve and modulate the gut microbiota have great attention in recent years from these using probiotic microorganisms which proved several effects in health improvement [1921]. Probiotics are defined according to [22] as live microorganisms that provide a health advantage on the host. The action of probiotic is not only species specific but also a strain specific. Here we present the isolation and characterization of three vitamin-producing strains from human gut microbiota as potential probiotics candidates capable to protect rats from induced inflammation.

Materials and methods

Microorganisms and growth conditions

LAB isolates were grown on de Man, Rogosa & Sharpe (MRS) agar (Laboratories Conda S.A., Madrid, Spain) at 37°C. The indicator strains were obtained from the American Type Culture Collection (ATCC) and cultivated as follows: Staphylococcus aureus (ATCC-6538) on brain heart infusion (BHI) agar (Oxoid, Basingstoke, UK); Escherichia coli (ATCC- 8739), Bacillus subtilis (ATCC-6633) and Pseudomonas aeruginosa (ATCC-9027) on Luria Bertani (LB) agar (Oxoid, Basingstoke, UK); Candida albicans (ATCC 10231) on yeast mold (YM) agar (Difco, Franklin Lakes, NJ, USA).

Isolation of lactic acid bacteria (LAB) from human fecal samples

Fecal samples were collected from different healthy people aged up to 60 years old. The study protocol was approved by the Research Ethics Committee of Faculty of Pharmacy, Badr University in Cairo (Egypt) no. PM-101-AH and written informed consent was obtained. The samples were suspended in phosphate buffer and stored at—40°C. Serial dilutions of each fecal sample were incubated anaerobically using the anaerobic jar and the anaerobic AnaeroGen (Oxoid Basingstoke, UK) at 37°C on (MRS) agar (Laboratories Conda S.A., Madrid, Spain) plates containing 0.05% w/v L. cysteine (Loba Chemie, Mumbai, India). After 48 hours of incubation single colonies were picked from each plate and examined by gram staining and catalase test before storage in 40% glycerol at -40°C [23].

Genomic DNA extraction and PCR

Genomic DNA was extracted using the AxyPrep bacterial genomic DNA miniprep kit (Axygen Biosciences, Union City, CA, USA) from freshly overnight cultures following the manufacturer’s instructions. PCR was carried out on a thermal cycler system T100 (Bio Rad, Hercules, CA, USA) using PCR Master Mix (Fermentas Life Sciences, Vilnius, Lithuania), The PCR amplifications were examined by electrophoresis purification was done using a QIA quick PCR purification kit (Qiagen, Hilden, Germany). The primers used are as listed in (Table 1) and obtained from Bioserve Company (Cairo, Egypt).

Table 1. Primers used during this study.

Primer name Primer sequence 5′–3′ Target gene References
Folk- F CCATTTCCAGGTGGGGAATC folK [18]
FolK- R GGGGTGGTCCAAGCAAACTT
Folp- F CCASGRCSGCTTGCATGAC folP
Folp- R TKACGCCGGACTCCTTTTWY
Rib A- F TTTACGGGCGATGTTTTAGG ribA
Rib A- R CGACCCTCTTGCCGTAAATA
RibB- F AGTAAACGGAACGGGCAAGC ribB
RibB- R GTTGACCAGGGCACCAACTG
Rib G- F TGGKAAGACGCCKCCKTGT ribG
Rib G- R TTCACCAAYCARAATYGCTTGA
Rib H- F AGGGCGAAACCGACCACTAC ribH
Rib H- R CGATTGGGCAGTCATCGAAC
FD1 CCGAATTCGTCGACAACAGAGTTTGATCCTGGCTCAG 16S rRNA [20]
RD1 CCCGGGATCCAAGCTTAAGGAGGTGATCCAGCC

Screening the isolates for the genes encoding the biosynthesis of folate and riboflavin

Genomic DNA isolated from the bacterial isolates were screened by PCR to detect the genes coding for the enzymes involved in the folate and riboflavin biosynthesize pathway according to Turpin et al. [24] and the primers targeted these genes are listed in Table 1. For folate, the isolates were screened for the signature two genes; folP gene encoding dihydropteroate synthase and folK gene encoding 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase [25]. For riboflavin, isolates were screened for the four genes involved in its production ribA encoding 3,4-dihydroxy-2-butanone-4-phosphatesynthase, ribG encoding Di amino hydroxyl phosphor ribosyl amino-pyrimidine deaminase, ribB encoding riboflavin synthase subunit alpha, and ribH encoding 6,7-dimethyl-8-ribityllumazine (lumazine) synthase.

The amplified fragments corresponding to each gene were checked on agarose gel then sequenced.

Molecular identification

The selected isolates were identified by amplification and sequencing of their 16S rRNA genes using universal primers (Table 1) [26].

DNA sequencing and analysis

Sequencing was conducted using the dideoxy chain termination method [27] and sequence similarity was determined by the BLAST search tool within the National Centre of Biotechnology Information [28] and the sequences aligned with the CLUSTALW interface and phylogenetic tree was created in MEGA7.0 (http://www.megasoftware.net/.

Nucleotide sequence accession numbers

The amplified sequences of the 16S rRNA gene have been deposited in the GenBank database under accession numbers.

Acid tolerance assay

Cultures were grown in MRS broth at 37°C for 24 hours, and then subcultured in 10 mL of MRS broth adjusted to pH 2.0. The initial bacterial concentration was determined by viable count determination on MRS; the samples were incubated for 3 hours at 37°C. The cells were serially diluted 10-fold in PBS (pH 7.0). The residual viable count was determined by plate counting on MRS agar after 48 hours of incubation. The survival rate was calculated as the percentage of colonies grown on MRS agar compared to the initial bacterial concentration [29].

Bile salt tolerance

The method of Gilliland et al. [30] was used to determine bile tolerance. The isolates were inoculated into MRS broths supplemented with different concentration of oxgall bile (0.3, 0.7 and 2% w/v) (Sigma-Aldrich, St. Louis, MO, USA) then incubated for 24 hours at 37°C onto MRS agar plates. The viable count was done at 0, 3 and 24 hours and the percentage of the survival was calculated compared to the control which has no bile. The experiment was performed in triplicate.

Susceptibility to antibiotics

Antibiotic susceptibilities for the selected isolated were tested using disc diffusion method against the following antibiotics, ampicillin, amoxicillin, chloramphenicol, kanamycin, tetracycline, ciprofloxacin, gentamycin, vancomycin, oxytetracycline, and erythromycin as described by Wayne [31]. The antibiotic discs were obtained from bioMerieux (Lyon, France). Diameters of inhibition zones were measured in nm and compared to the Clinical and Laboratory Standards Institute (CLSI) as resistant, intermediate, and susceptible.

Antimicrobial activity

Antimicrobial activity of the isolates against pathogenic bacteria; E. coli, S. aureus and C. albicans was determined by standard well diffusion method using Mueller Hinton Agar (MHA) plates [32]. The 100 ul inoculum (108 CFU/ml) of each bacterium was spread on MHA plates. Wells were made in each inoculated plate and filled with 30 μl of neutralized cell free supernatant (pH 6.5) of isolates obtained after 24 hours growth in MRS broth. Ciprofloxacin (30 mg/ml) was used as positive control and MRS broth was used as negative control. All MHA plates were incubated at 37°C for 24 hours and were examined for inhibition zones >1 mm. Each test was performed in triplicate.

Blood hemolysis

Hemolysin activity was assessed on Columbia blood agar (Oxoid) containing 5% v/v human blood after 48 hours of incubation at 37°C [33].

HPLC determination of riboflavin and folic acid by bacterial isolates

One ml from an overnight culture (24 hours) was centrifuged at 14,000 g for 5 min. and the supernatant was taken and analyzed by HPLC at the central laboratory of the National Research Centre, Egypt based on the method of Klejdus et al. 2004 [34]. HPLC analysis was carried out by diluting the sample 10 fold in Milli Q water and 10 μl was injected onto the HPLC, Separation was performed on a Shimadzu HPLC system with SPD-10A VP detector, a Shimadzu LC-10AD constant-flow pump, and a recorder (Shimadzu Corporation, Kyoto, Japan). The chromatographic column was LiChrospher® RP-18 (250 mm x 4.6 mm, 5 μm film thicknesses). The column was kept at room temperature a flow rate of 0.7 ml/min with a total run time of 12 min. Separation was carried out by gradient elution with Fluorite (A) and Acetonitrile containing water (75: 25) (B). Detection wave length for detection of riboflavin and folate was set at 254 nm. Riboflavin and folic acid (Loba Chemie PVT LTD) were used as standard, the quantification of the peak area was performed.

In vivo evaluation of the vitamin producing- isolates in treatment of colitis

Rats

36 Male wistar rats aged 6 weeks weight of about 200 mg were obtained from Cairo University and the study protocol was approved by the Research Ethics Committee of Faculty of Pharmacy, Badr University in Cairo (Egypt) no. PM-101-AH and written informed consent was obtained. The rats were kept at the animal house of the National Research Centre (NRC), Egypt and rats were handled with care. The room was at 18–20°C and 20% humidity under a 12 hours light/dark cycle and the rats were fed with commercial riboflavin-free diet and water. At the end of the experiment, animals were sacrificed by decapitation under anesthesia by well-trained person using thiopental (50 mg/kg) as demonstrated previously [35] according to AVMA Guidelines for the Euthanasia of Animals: 2020 Edition.

Induction of colitis in rats by acetic acid

Colitis was induced in rats by a rectal enema with 1 mL of 3.5% (v/v) acetic acid diluted in saline. Acetic acid solution was administered through a polyethylene catheter inserted into the rectum by 4.5 cm from the anus [36]. Rats without induction of colitis obtained rectal enema with an aqueous saline solution administered at the same manner as a solution of acetic acid in animals with induction of colitis.

Administration of probiotic isolates and induction of colitis

The design of the experiment is presented in Fig 1 where the oral method was used for administration of the selected strains to the experimental rats where the dose contained 109 CFU in volume 200 μL of PBS. The rats were divided into six groups. Each group contained 6 rats: control group and ulcerative group received 200 μL of PBS, the treated four groups received the selected strain as follows; A: WNYM01; B: WNYM02; C: WNYM03; M: mixture of the three stains. Administration was done in daily dose for 14 days then followed by the colitis induction in day 15 for all rat groups except the control group. Then each treated group continued receiving its daily dose from selected strain and ulcerative group continued receiving PBS for 4 days and the experiment ended by sacrificing and samples were collected as previously described by Cortes-Perez et al. [37].

Fig 1. Experimental design.

Fig 1

Rats were divided to 6 groups (n = 6 per group), the groups received the probiotic isolates or PBS daily for 14 days then on day 15 of the experiment, the groups were induced for colitis by acetic acid followed by continues the administration of the probiotics to treatment groups and PBS to the ulcerative group for 4 days before be sacrificed. The control group received PBS only without any colitis induction. The treatment groups received the isolates orally before and after the colitis induction as follows; (A), WNYM01; (B), WNYM02; (C), WNYM03; (M), Mixture of WNYM (01, 02 and 03).

Macroscopic assessment of colonic damage

Macroscopically visible injuries such as thickening, shortening, hyperemia, and necrosis were blindly scored from 0–100% based on increasing order of severity as described by Ballester et al. [38] and Motavallian-Naeini et al. [39]. The mean scores were presented as the Disease Activity Index (DAI) of the colon.

Microscopic assessment of colonic damage

Samples of the distal colons were fixed immediately in 10% formaldehyde, embedded in liquid paraffin, cut into transverse sections of 5 μm thick using a Leica RM 2125 Microtome (Leica Biosystems, Wetzlar, Germany), and then mounted on glass slides and stained with haematoxylin and eosin (H&E). Microscopic changes such as necrosis, fibrosis, hyperemia, epithelial damage, ulceration, infiltration, and submucosal abscesses were scored on a 0–4 scale where 0 denotes no detectable damage and 4 denotes most severe damage [40]. Microscopy images for each group obtained with a magnification of 50X.

Determination of the anti-inflammatory markers (IL-10 and TNF-α)

The interlukin-10 (IL-10) and Tumor Necrosis Factor Alpha (TNF-α) were tested by ELISA in the cytoplasmic extracts from homogenate rats intestinal tissues. Protein content in tissue homogenate was determined according to the method of Bradford et al. [41]. ELISA kits “IL-10 Cloud Clone corp” (USA) and “Rat (TNF-α)” (Abbexa, UK) were used according to the manufacturer instructions. Data are represented as pg/mg total proteins and the determinations were performed in triplicate.

Determination of lipid peroxidation marker (TBARS) and oxidative stress biomarkers (GSH)

Thiobarbituric Acid Reactive Substances (TBARS) and Glutathione (GSH) were tested by ELISA [42, 43] in the cytoplasmic extracts from homogenate rat’s intestinal tissues. Kits used were TBARS Assay kit (Cayman Chemicals, USA) and Glutathione Fluorometric Assay Kit (GSH, GSSG and Total) (BioVision, USA) according to the manufacturer’s instructions. Data are represented as μg/mg total proteins and the determinations were performed in triplicate.

Statistical analysis

Data analysis was carried out using ANOVA test p value <0.05 was considered significant. Experiments were done in triplicate unless stated otherwise and all data was presented as mean ± standard deviation.

Results

Isolation of LAB from human feces

Initially, 150 gram-positive, catalase- negative isolates (data not shown) were selected from the incubation of the fecal samples on MRS agar plates. These isolates were evaluated for their tolerance to high acidity at pH 2.0 and alkaline conditions at pH 9.0. As a result, 49 isolates were picked for further screening according to their tolerance to low pH value by giving 80–85% survival after incubation for 3 hours at pH 2.0 in addition to their tolerance to the high pH value by showing 95% survival at pH 9.0 (Table 2).

Table 2. Screening the isolates for pH tolerance and the presence of folic genes (folk, folP) and riboflavin genes (ribA, ribB, ribG, ribH) within their genomic DNA by PCR using the specific primers as listed in Table 1.

Isolate No Isolate pH tolerance Expected PCR product size (Base Pair) for the tested genes
Code Survival % Survival % folk folP ribA ribB ribG ribH
(pH 2.00) (pH 9.00) 214 bp 261bp 121 bp 235 bp 351bp 179 bp
1 1AM 85.5 ± 1.3 95.3 ± 2.3 + + - + + +
2 1BM 81.5 ± 1.7 97.1 ± 2.6 + + - + + +
3 2AM 82.3 ± 1.2 95.1 ± 2.3 + + - + + +
4 3BM 85. 0 ± 1.4 96.0 ± 2.7 - - + + + +
5 3BB 82.5 ± 1.8 95.1 ± 2.3 - - + + + +
6 4AM 85.0 ± 1.2 96.2 ± 1.8 + + - - - +
7 4BM 85.3 ± 1.4 95.3 ± 1.2 + + + + + +
8 4CM 83.5 ± 1.1 97.1 ± 1.9 + + - + + +
9 SH1 82.3 ±1.6 96.3 ± 2.5 + + - - - -
10 SH2 81.7 ± 1.9 95.1± 2.0 - - - - - -
11 SH3 85.0 ± 1.3 95.1± 2.0 + + + + + +
12 SH5 84.5 ± 1.1 95.1± 2.3 + + - + + -
13 SH6 84.5 ± 1.7 95.1 ± 2.3 - - - + - -
14 H1A 80.4 ± 1.2 95.2 ± 2.1 - + - - - -
15 H2B 81.2 ± 1.2 95.3 ± 2.0 - - - - - -
16 H3C 85.2 ± 1.6 95.0 ± 1.9 + + + + + +
17 H4D 80.7 ± 2.1 95.6 ± 2.3 - - - - - -
18 H5G 80.5 ± 1.9 95.1 ± 2.2 - - - - - -
19 H6H 80.8 ± 2.3 95.0 ± 1.8 - - - + - -
20 M6 85.5 ± 2.5 97.1 ± 2.3 - - - + - +
21 F1 81.6 ± 1.2 95.3± 2.4 - - - - - --
22 F2 81.5 ± 1.6 95.1± 2.3 - - - - - -
23 F7 82.1 ± 1.1 95.3 ± 2.1 - - - - - -
24 F8 82.0 ± 1.3 95.1 ± 2.6 - - - - - -
25 9C 85.1 ± 1.4 97.1 ± 2.1 + + + + + +
26 8D 84.6 ± 1.7 96.3 ± 2.2 + + + + + +
27 FA1 80.0 ± 1.2 95.9 ±1.9 - - - - - -
28 FA3 80.3 ± 1.5 95.5 ±2.3 - - - - - -
29 FA4 80.6 ± 1.2 95.6 ± 2.4 - - - - - -
30 FA5 81.0 ± 2.1 95.1 ± 2.8 - - - - - -
31 S1 83.5 ± 1.6 95.0 ± 2.9 - - - - - -
32 S3 83.8 ± 2.3 95.2 ± 2.1 - - - - + -
33 S4 82.9 ± 1.9 95.1 ± 2.3 - - - - - -
34 S5 84.6 ± 1.6 95.8 ± 2.9 - - - - - -
35 S6 85.1 ± 1.4 95.5 ± 3.3 - + - - - -
36 TH 1 83.5 ± 1.2 95.3 ± 2.8 - - - - - -
37 TH2 83.7 ± 1.6 95.0 ± 2.4 - - - - - -
38 TH3 82.9 ± 1.9 95.0 ± 2.5 Two bands 500 650 1000 - -
39 TH4 85.5 ± 2.6 95.2 ± 2.8 Two bands Two bands - 500 - -
40 TH5 83.5 ± 1.7 95.3 ±3.0 Two bands Two bands - 500 - -
41 TH6 83.4 ± 1.2 95.1 ± 3.2 Two bands - - - - -
42 SA1 81.9 ± 1.7 96.4 ± 2.5 - - - - - -
43 SA2 82.0 ± 1.3 95.8 ± 2.8 - - - - - -
44 SA3 82.3 ± 2.1 95.0 ± 2.3 - + + + + +
45 SA4 83.0 ±1.2 96.1 ± 1.9 - + - + - -
46 FM1 85.3±1.0 95.1 ± 1.3 - - - - - -
47 FM2 84.9±1.3 97.0 ± 2.5 - - + + + +
48 FM3 85.1±1.6 96.2 ±2.0 - + + - - -
49 FM4 83.3±2.3 95.3 ±3.1 + - 1000 + +

pH tolerance data represent the means ± SDs of three independent experiments.

For gene detection by PCR: (-) no bands, (+) bands in the range of the predicted size. The three selected isolates are marked in bold.

Screening the isolates by PCR for the presence of riboflavin and folate genes

The genomic DNA was extracted from the isolates and screened by PCR for the presence of the genes involved in the biosynthesis of each of the two vitamins riboflavin and folate. The four riboflavin genes ribA, ribB, ribG, and ribH which involved in its production were used for the detection. The PCR results (Table 2) revealed the positive of 8 isolates out of the 49 isolates by giving amplification products in the predicted sizes as follows; 121 bp, 235 bp, 351bp, 179 bp for genes ribA, ribB, ribG, and ribH respectively. The signature genes folP and folK were used for detection the presence of folate biosynthesis genes within the genome of the isolates, the PCR results (Table 2) showed 12 isolates out of 49 isolates are positive to the two genes by giving the amplified products in the predicted sizes; 261bp and 214 bp for folP and folk genes respectively. According to the PCR results, three isolates have been selected as they showed the presence of tested genes from both riboflavin and folate (Fig 2A and 2B). Each PCR fragments from the three strains were checked by sequencing and analysis by blast which revealed their identical by 98–100% to the corresponding genes from several Pediococcus acidilactici strains available in the database as strains with accession no: CP067392.1, CP035151.1, CP068106.1, CP028249.1, CP028247.1, CP066066.1, CP05342.1, CP018763.1, CP050079.1, CP053421.

Fig 2.

Fig 2

A: PCR products for detection of riboflavin and folic genes in the selected isolates using specific primers as listed in Table 1. Lane1, 1 Kb ladder; lane 2, 3, 4, PCR products for ribA gene from WNYM01, WNYM02, WNYM03; lane 5, 6, 7, PCR products for ribH gene from WNYM01, WNYM02, WNYM03; lane 8, 9, 10, PCR products for folK gene from WNYM01, WNYM02, WNYM03; lane 11, negative control; lane 12, 13, 14, PCR products for ribG gene from WNYM01, WNYM02, WNYM03. B: Continue PCR products for detection of riboflavin and folic genes in the selected isolates using specific primers as listed in Table 1. Lane1, negative control; lane 2, 3, 4, PCR products for ribB gene from WNYM01, WNYM02, WNYM03; lane 5, 6, 7, PCR products for folP gene from WNYM01, WNYM02, WNYM03; lane 9, 100bp ladder.

Molecular identification of the selected isolates

The amplified 16S rRNA products at the expected size approximately 1.5 Kb of the three isolates were checked on 1% agarose gel (Fig 3A) then were sequenced and clustered with NCBI database sequences. All the three isolates showed 100% identical to Pediococcus acidilactici strains available in the NCBI database and phylogenetic tree was created (Fig 3B). They were named as P. acidilactici WNYM01, P. acidilactici WNYM02 and P. acidilactici WNYM03 and their partial sequences were submitted to GenBank under the accession numbers MW856830, MW856831 and MW865736 respectively.

Fig 3.

Fig 3

A: PCR amplification of the 16S rRNA gene from the selected isolates using universal primer set as listed in Table 1. Lane1, 100bp ladder; lane 2, WNYM01, lane 3, WNYM02; lane 4, WNYM03; lane 5, negative control. B: Phylogenetic tree of the isolated strains for molecular identification based on their 16S rRNA gene. Blast search at NCBI data base indicate their 16S rRNA gene are 100% identical to that belong to Pediococcus acidilactici strains which their accession numbers are listed on the tree. Phylogenetic tree was performed using MEGA7 software.

Evaluation of the probiotic criteria of the selected vitamin producing-isolates

Bile salt tolerance

The three isolates incubated with different concentration of bile salt and the result listed in Table 3. The three isolates showed resistance to 0.3 and 0.7% of bile salt in the MRS media up to 24 hours with a very good survival rate range from 92–97.5%. Only strain WNYM03 showed survival 73% in the 2% bile salt for 3 hours and cannot survival for longer where it shows only 15% survival after 24 hours.

Table 3. Tolerance of isolated Pediococcus acidilactici strains to bile salts.
Bile salt tolerance
Survival (%) Survival (%) Survival (%)
0.3% bile 0.7% bile 2% bile
Strain name 3 h 24 h 3 h 24 h 3 h 24 h
WNYM01 98.5 ± 1.0 96.5 ±2.1 95.5 ± 2.1 93.0± 1.4 73 ± 2.8 15.2 ± 2.5
WNYM02 97.5 ± 1.2 96.0± 1.4 96.0 ± 1.4 94.0 ± 1.2 ND ND
WNYM03 95.5 ± 2.1 94 ± 1.4 93.5 ± 0.7 92.0 ± 0.7 ND ND

Data represent the means ± SDs of three independent experiments. ND, not detected

Antibiotic susceptibility

The three isolates were tested for susceptibility to ten antibiotics listed in Table 4 using the agar diffusion method. The three showed similar pattern except for amoxicillin and Co-trimoxazole where WNYM03 was sensitive and the other two strains were intermediate. In addition, they all showed susceptibility to chloramphenicol, erythromycin, gentamycin, kanamycin and tetracycline. They all were resistant to ampicillin, ciprofloxacin and vancomycin.

Table 4. Susceptibility of isolated Pediococcus acidilactici strains to antibiotics.
Strain name Amp Amx Ery Cip Gen Cm Van Tet Kan Cot
10 ug 30 ug 15 ug 15 ug 10 ug 30 ug 30 ug 30 ug 30 ug 25 ug
WNYM01 R I S R S S R S S I
WNYM02 R I S R S S R S S I
WNYM03 R S S R S S R S S S

Diameters of inhibition zones were measured and results expressed in terms of resistant (R), intermediate (I) and susceptible (S) according to cut off levels proposed by the NCCLS [61]. Data represent three independent experiments. Amp, ampicillin; Amx, Amoxicillin; Ery, erythromycin; Cip, ciprofloxacin; Gen, Gentamycin; Cm, chloramphenicol; Van, Vancomycin; Te, tetracycline; Kan, Kanamycin; Cot, Co-trimoxazol.

Antimicrobial activity

The antimicrobial activity of our strains was determined using an agar well diffusion test against the pathogenic strains. As shown in Table 5 all the three strains inhibited the growth of S. aureus, E. coli, P. aeruginosa and B. subtilis, while they have no effect on Candida albicans.

Table 5. Antimicrobial activity of the isolated Pediococcus acidilactici strains.
Inhibition Zone (mm)
WNYM01 WNYM02 WNYM03
C. albicans ND ND ND
S. aureus 23 ±0.05 24 ±0.02 23 ±0.05
Bacillus 22 ±0.02 22 ±0.01 22 ±0.03
E.coli 22 ±0.03 22 ±0.01 22 ±0.01
P. aeruginosa 25 ±0.02 20 ±0.02 20 ±0.01

Data represent the means ± SDs of three independent experiments. ND, not detected.

Blood hemolytic activity

Hemolytic activities of the three P. acidilactici isolates were determined on blood agar plates. The three strains showed γ hemolytic, which means no hemolytic activity.

HPLC detection of the riboflavin and folic acid production by selected isolates

The detection of the production of the two vitamins was done by HPLC (Table 6) where the peaks identification in the supernatant of the tested three strains was based on the retention time of the folic acid standard at 2.242 min. and the strains gave peak height as 17.27, 20.14, and 20.94% for P. acidilactici WNYM01, P. acidilactici WNYM02 and P. acidilactici WNYM03 respectively. And based on the retention time of the riboflavin standard at 3.25 min where the three strains P. acidilactici WNYM01, P. acidilactici WNYM02 and P. acidilactici WNYM03 gave peak height as 21.19, 38.83, and 25.62% respectively.

Table 6. Detection of folic acid and riboflavin production by the isolated P. acidilactici strains was done using HPLC.

The culture supernatant from each strain was tested and1mg/ml of each folic acid and riboflavin was used as standard, the running volume was 10 μl, the retention time and the peak (area—height) listed.

Folic (1mg/ml) WNYM01 WNYM02 WNYM03
Retention time 2.242 2.275 2.317 2.458
Peak Area 417914 8542069 8360937 9803561
Area % 64.378 26.121 25.519 28.925
Peak Height 44779 289023 288480 297490
Height % 76.081 17.274 20.141 20.939
Riboflavin (1mg/ml) WNYM01 WNYM02 WNYM03
Retention time 3.250 3.183 3.217 3.192
Peak Area 2007067 4833985 11273995 11242746
Area % 86.364 14.782 34.410 33.171
Peak Height 95784 354613 398349 363989
Height % 81.438 21.195 27.811 25.620

In vivo evaluation of the isolated P. acidilactici strains in treatment of acetic induced-colitis rats

The three isolated P. acidilactici strains were evaluated individually and in mixture in vivo for their effect on colitis in rats in four treatment groups: A (WNYM01), B (WNYM02), C (WNYM03) and M (mix of the three strains) compared to the control group and the ulcerative group. The treatment groups received our isolated P. acidilactici strains in daily dose before and after the induction of the colitis. Thus all the groups were critically evaluated in particular to the following points.

Gross findings

The gross findings in the colon segment of the experimental rats showed that; colon of control rats exhibited normal wall thickness, mucous membrane, muscular and serosal layer. On the other hand, the colon segment of the ulcerative group which did not receive any of the three isolates, displayed hemorrhagic inflammation and edematous swelling in their mucosae. The treatment groups A, B, C and M which received isolates WNYM01, WNYM02, WNYM03, and mix of the three respectively before and after the colitis induction showed healing in the ulcerative lesions in addition to normal colon segment with healthy mucosa (Fig 4).

Fig 4. Gross photograph of rat’s colon segment showing the appearance differences among the groups in wall thickness, mucous membrane, muscle coat and serosa.

Fig 4

The rat groups received the probiotic isolates or PBS daily for 14 days then induction for colitis by acetic acid on day 15 of the experiment followed by continues the administration for 4 days before be sacrificed. The control group received PBS only without any colitis induction. The treatment groups received the isolates orally before and after the colitis induction as follows; (A), WNYM01; (B), WNYM02; (C), WNYM03; (M), Mixture of WNYM (01, 02 and 03).

Microscopic examination

The histopathological examination of rat colon in the all experimental groups exhibited the following findings:

The colon segment in the control group (Fig 5) showed normal histological structure, including the mucosa (Lamina epithelialis, Lamina muscularis mucosa and lamina propria), the submucosa, the muscular coat (inner circular and outer longitudinal muscle fibers) and the serosa. On the other side in the ulcerative group (Fig 5), the colon segment illustrated multifocal mucosal ulcerations accompanied with severe tissue damage in the entire mucosal layers, in addition, severe inflammatory reaction with congestion in mucosal and submucosal blood vessels were also pronounced. Massive necrosis and desquamative changes were found in the superficial and deep epithelial cell associated with leukocyte infiltration mainly lymphocytes and a few neutrophils. The colon glands found focally deformed with no secretory activity.

Fig 5. Rat’s colon segment showing the histo-morphological structures differences among the groups, including the mucosa (Lamina epithelialis, Lamina muscularis mucosa and lamina properia), the submucosa, the muscular coat (inner circular and outer longitudinal muscle fibers) and the serosa (arrows).

Fig 5

Scale bars 50 um, 100 um. The Rat groups received the probiotic isolates or PBS daily for 14 days then induction for colitis by acetic acid on day 15 of the experiment followed by continues the administration for 4 days before be sacrificed. The control group received PBS only without any colitis induction. The treatment groups received the isolates orally before and after the colitis induction as follows; (A), WNYM01; (B), WNYM02; (C), WNYM03; (M), Mixture of WNYM (01, 02 and 03).

The rat colon segment in the treatment groups (Fig 5) which received the three strains individually (A, B, C) or mixture of the three (M), exhibited normal histological features, as intact mucosal, submucosal, muscular and serosal layers. In addition, a healed ulcerative lesion with regeneration of the mucosal epithelium was observed in all the tested groups and the regenerated epithelial cells showed focal hyperplastic changes with hyperchromatic nuclei (regenerative signs). The mucosal proximity of the site of the healed ulcer greatly infiltrated by inflammatory cells mostly lymphocytes and plasma cells. The submucosa markedly replaced by aggregated and or follicular hyperplastic lymphoid cells.

Assessment of inflammatory markers (TNF-α and IL-10)

TNF-α level was significantly increased in the ulcerative rat group by expressing 407.5 pg/mg compared to the control group and the treatment groups A, B, C, M by expressing 104–160 pg/mg (Fig 6A) on the other hand, IL10 was significantly decreased by expressing 121 pg/mg compared to the control group (314 pg/mg) and treatment groups (229.5–281.5 pg/mg (Fig 6B).

Fig 6. Levels of inflammatory markers in the cytoplasmic extracts from homogenate rat’s intestinal tissues.

Fig 6

(A) tumor necrosis factor-α (TNF-α) and tissue (B) interlukin-10 (IL-10). The rat experimental groups: Control, received PBS only; Ulcerative, received PBS and colitis induction; A, received WNYM01 + colitis induction; B, received WNYM02 + colitis induction; C, received WNYM03 + colitis induction. M, received Mixture of WNYM (01–03) + colitis induction. Three triplicate experiments were independently performed. Data are presented as the mean ± standard deviation.

Assessment of lipid peroxidation marker (TBARS) and oxidative stress biomarkers (GSH)

Compared to the ulcerative rat group, both the control group and treatment groups verified significant decrease in TBARS contents (2.2–2.6 μg/mg) (Fig 7A) and in GSH contents (0.8–1.1μg/mg) (Fig 7B).

Fig 7. Levels of lipid peroxidation marker (TBARS) and oxidative stress biomarkers (GSH) in the cytoplasmic extracts from homogenate rat’s intestinal tissues.

Fig 7

(A), thiobarbituric acid reactive substances (TBARS) and (B), glutathione (GSH). The rat experimental groups: Control, received PBS only; Ulcerative, received PBS and colitis induction; A, received WNYM01 + colitis induction; B, received WNYM02 + colitis induction; C, received WNYM03 + colitis induction. M, received Mixture of WNYM (01–03) + colitis induction. Data are presented as mean ± S.D. (n = 3). Mean differences are significant (p < 0.05).

Discussion

Vitamin B2 (Riboflavin) and B9 (folate) are essential vitamins for human health, vital metabolic process, activation the immune cells and protect from diseases. Specific species of gut microbiota play main role in supply the human body with the sustainable amount of the essential vitamins. Any unbalance in the microbiota composition or diversity could lead vitamins deficiency and metabolic diseases. Probiotics consider an effective strategy to restore the gut microbiota and keep wellbeing. As the action of probiotic is strain specific, in this study we collected human fecal samples to isolate vitamin producer LAB as potential probiotics. The isolation was based on gram positive and catalase negative followed by screening the presence of biosynthesis genes; folP and folK for folate and ribA, B, G, H for riboflavin. Three isolates were chosen out of 49 isolates according to their PCR positive to the six target genes which confirmed by sequencing in addition to their tolerance to pH 2.0, the principle criteria for survival through the stomach. Their identification on the species level was based on amplification and sequencing 16S rRNA gene which was analyzed using blast research at NCBI and the results revealed that all of them belong to P. acidilactici strains available in the database by 100% identical. Our three strains named as P. acidilactici WNMY01, P. acidilactici WNMY02 and P. acidilactici WNMY03 met the probiotic criteria by expressing tolerance to alkaline condition (pH 9.0) 95% survival and to bile salt by giving > 90% survival to 0.7% bile salt for 24 hours and > 50% survival to 2% bile salt for 3 h these results are competing to P. acidilactici B14 showed 72.4% in 0.3% bile salt [44] while P. acidilactici SMVDUDB2 showed 80% at 0.3% - 0.5% bile salt [45]. Furthermore, our three strains showed antibacterial activity against the four tested bacteria; the gram positive (B. subtilis and S. aureus) as well as the gram negative (E. coli and P. aeruginosa). Their competitive and inhibition ability suggest them as alternative to overcome the drug resistant pathogens. This ability could be due to substances as lactic acid, hydrogen peroxide, and bacteriocins production as detected by other P. acidilactici strains [46, 47].

Their production of the two vitamins was detected by HPLC, thus suggested them as potential probiotics which able to colonize the gastrointestinal tract and provide the B2 and B9 vitamins to the host.

For assessment their safety, they were tested for susceptibility to ten antibiotics where they showed susceptibility or intermediate to seven antibiotics; the gram-positive spectrum antibiotic erythromycin, the broad-spectrum antibiotics tetracycline and the aminoglycosides gentamicin, amoxicillin and co-trimoxazole in addition to kanamycin and chloramphenicol these results are in agreement to previous results on LAB [48, 49]. They all were resistant only three antibiotics; vancomycin in agreement to the results obtained by Singla et al. [50] and Bhagat et al. [45] in addition to ampicillin, ciprofloxacin.

Administration of the three strains solely or as mixture to rats before and after the induction of colitis by acetic acid resulted in protection against damage and inflammation. The anti-inflammatory effect on the treated groups was proved by the assessment of inflammatory markers (TNF-α and IL-10). They showed a remarkable reduction of TNF-α by giving 160.5–131 pg/ mg compared to the ulcerative group which showed high levels 407.5±17.5 pg/ mg. The TNF-α plays a crucial roles in the pathophysiology of inflammatory bowel disease [51, 52] and has the ability to negatively affect the mucosal immune system and causing colonic damage. These findings are in agreement with conclusion reported by Liu et al. [53]; Kanmani et al. [54]; Vincenzi et al. [55] about the action of probiotics in suppress TNF-α release. On the other hand, the three strains and their mixture showed significant increase in the IL-10, the best key anti-inflammatory cytokine in the immune response [56] as they released IL-10 as 281.5–229.5 pg/mg compared to the ulcerative group which showed low level of IL-10 as 121±4.0 pg/mg.

There is increase evidence that colonic inflammation, both in human patients and experimental animals, is related to increased release of reactive oxygen metabolites and nitric oxide levels. The assessment of lipid peroxidation marker (TBARS) and oxidative stress biomarkers (GSH) in rats tissues revealed the action of our three strains and their mixture in significant reduction of their value to (2.2–2.6 μg/mg) TBARS and (0.8–1.1μg/mg) GSH compared to the ulcerative group which release 6.95±0.45 μg/mg TBARS and 1.617±0.03 μg/mg GSH. This reduction in the TBARS and GSH markers could have protective effects against inflammation. Similar results reported by Watanabe et al., 2020 [57] as concluded the effective of L. plantarum P1-2 and P. pentosaceus Be1 for reducing oxidative stresses in vivo.

The anti-inflammatory properties of the three strains could be also due to the riboflavin and folic acid effects. Different studies reported the anti-inflammatory effect of riboflavin and folic acid. Leblanc et al., 2020 [58] and the ability of folic acid and riboflavin producer LAB to treat inflammation in animal models was reported by Levit et al., 2017 [59] and Levit et al., 2020 [60].

Conclusions

Here we represent the isolation, characterization and in vivo evaluation of P. acidilactici WNYM01, WNYM02 and WNYM03 strains which containing the screened biosynthesis genes for vitamin B2 and B9. The administration of our three strains of P. acidilactici to experimental rat groups before and after the induction of colitis prevent tissues damage and was associated with a reduction of inflammatory and oxidative stress biomarkers, while increasing the vital cytokine for immune response. These findings are suggesting potential novel probiotic candidates for modulation the gut microbiota and pharmaceutical industries. However, complete genome sequence for these valuable strains is in progress.

Supporting information

S1 Table. The antibiotics susceptibility of the isolates; WNYM01, WNYM02 and WNYM03.

(DOCX)

S2 Table. Assessment of inflammatory markers in the cytoplasmic extracts from homogenate rat’s intestinal tissues tumor necrosis factor-α (TNF-α) and intelukin-10 (IL-10).

The rat experimental groups: control, received PBS only; Ulcerative, received PBS and colitis induction; A, received WNYM01 + colitis induction; B, received WNYM02 + colitis induction; C, received WNYM03 + colitis induction. M, received Mixture of WNYM (01–03) + colitis induction. Data are presented as mean ± S.D. (n = 3). *Significance compared to Ulcerative. Mean differences are significant (p < 0.05).

(DOCX)

S3 Table. Assessment the levels of lipid peroxidation marker thiobarbituric acid reactive substances (TBARS) and oxidative stress biomarkers glutathione (GSH) in the cytoplasmic extracts from homogenate rat’s intestinal tissues.

The rat experimental groups: control, received PBS only; Ulcerative, received PBS and colitis induction; A, received WNYM01 + colitis induction; B, received WNYM02 + colitis induction; C, received WNYM03 + colitis induction. M, received Mixture of WNYM (01–03) + colitis induction. Data are presented as mean ± S.D. (n = 3). * Significance compared to Ulcerative. Mean differences are significant (p < 0.05).

(DOCX)

Data Availability

All relevant data are within the paper, its Supporting Information files and GenBank under the accession numbers MW856830, MW856831 and MW865736.

Funding Statement

This research work was done at the National Research Centre (Egypt).

References

  • 1.Vaikunthanathan T, Safinia N, Lombardi G, Lechler RI. Microbiota, immunity and the liver. Immunol. Lett. 2016; 171: 36–49. doi: 10.1016/j.imlet.2016.01.008 [DOI] [PubMed] [Google Scholar]
  • 2.Dehler C E, Secombes C J, Martin S AM. Environmental and physiological factors shape the gut microbiota of Atlantic salmon parr (Salmo salar L.). Aquaculture. 2017; 467: 149–157. doi: 10.1016/j.aquaculture.2016.07.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gao X, Cao Q, Cheng Y, Zhao D, Wang Z, Yang H, et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc Natl Acad Sci U S A. 2018; 115(13):E2960–E2969. doi: 10.1073/pnas.1720696115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bellows L, et al. Water-soluble vitamins: B-complex and vitamin C. 2012. extension.colostate.edu/topic-areas/nutrition-food-safety-health/water-soluble-vitamins–bcomplex–and-vitamin-c-9-312/
  • 5.Mayo Clinic Staff. Vitamin deficiency anemia. 2016. mayoclinic.org/diseases-conditions/vitamin-deficiency-anemia/symptoms-causes/syc-20355025.
  • 6.Yoshii K, Hosomi K, Sawane K, & Kunisawa J. Metabolism of Dietary and Microbial Vitamin B Family in the Regulation of Host Immunity. Frontiers in nutrition. 2019; 6: 48. doi: 10.3389/fnut.2019.00048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gyorgy P. Investigations on the vitamin B 2 complex. I. The differentiation of lactoflavin and the ‘rat antipellagra’ factor. Biochem J.1935; 29: 741–759. doi: 10.1042/bj0290741 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Seekamp A, Hultquist DE, Till GO. Protection by vitamin B2 against oxidant-mediated acute lung injury. Inflammation. 1999; 23:449–460. doi: 10.1023/a:1021965026580 [DOI] [PubMed] [Google Scholar]
  • 9.Araki S, Suzuki M, Fujimoto M, Kimura M. Enhancement of resistance to bacterial infection in mice by vitamin B2. J. Vet. Med. Sci.1995; 57: 599–602. doi: 10.1292/jvms.57.599 [DOI] [PubMed] [Google Scholar]
  • 10.Mazur-Bialy A. I., & Pocheć E. Riboflavin Reduces Pro-Inflammatory Activation of Adipocyte-Macrophage Co-culture. Potential Application of Vitamin B2 Enrichment for Attenuation of Insulin Resistance and Metabolic Syndrome Development. Molecules (Basel, Switzerland). 2016; 21(12): 1724. doi: 10.3390/molecules21121724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Menezes RR, Godin AM, Rodrigues FF, Coura G, Melo I, Brito A, et al. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund’s adjuvant. Pharmacological reports. 2017; 69(5): 1036–1043. doi: 10.1016/j.pharep.2017.04.011 [DOI] [PubMed] [Google Scholar]
  • 12.Schramm M, Wiegmann K, Schramm S, Gluschko A, Herb M, Utermöhlen O, et al. Riboflavin (vitamin B2) deficiency impairs NADPH oxidase 2 (Nox2) priming and defense against Listeria monocytogenes. Eur J Immunol.2014; 44:728–41. doi: 10.1002/eji.201343940 [DOI] [PubMed] [Google Scholar]
  • 13.WHO/FAO. Vitamin and Mineral Requirements in Human Nutrition. 2nd ed. Report of a joint WHO/FAO Expert Consultation, Bangkok, Thailand 1998. Geneva: World Health Organization/Rome: Food and Agriculture Organization of the United Nations; (2004). [Google Scholar]
  • 14.Said HM. Recent advances in transport of water-soluble vitamins in organs of the digestive system: a focus on the colon and the pancreas. Am J Physiol Gastrointest Liver Physiol. 2013; 305:G601–10. doi: 10.1152/ajpgi.00231.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol.2009; 21:1105–11. doi: 10.1093/intimm/dxp095 [DOI] [PubMed] [Google Scholar]
  • 16.Kinoshita M, Kayama H, Kusu T, Yamaguchi T, Kunisawa J, Kiyono H, et al. Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon. J Immunol.2012; 189:2869–78. doi: 10.4049/jimmunol.1200420 [DOI] [PubMed] [Google Scholar]
  • 17.Bender A, Hagan K E, & Kingston N. The association of folate and depression: A meta-analysis. J. Psychiatr. Res. 2017; 95: 9–18. doi: 10.1016/j.jpsychires.2017.07.019 [DOI] [PubMed] [Google Scholar]
  • 18.Hinks TSC, Zhang XW (2020) MAIT Cell Activation and Functions. Front Immunol. 2020; 11:1014. doi: 10.3389/fimmu.2020.01014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kobyliak N, Conte C, Cammarota G, et al. Probiotics in prevention and treat-ment of obesity: a critical view. Nutr Metab. 2016; 13:14. doi: 10.1186/s12986-016-0067-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Azad MAK, Sarker M, Li T, et al. Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int. 2018; 2018:9478630. doi: 10.1155/2018/9478630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Joseph N, Clayton JB, Hoops SL, et al. Alteration of the Gut Microbiome in Normal and Overweight School Children from Selangor with Lactobacillus Fermented Milk Administration. Evol Bioinform Online. 2020; 16:1176934320965943. doi: 10.1177/1176934320965943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.FAO/WHO (2002). Guidelines for the Evaluation of Probiotics in Food. Paris: FAO,1–11. [Google Scholar]
  • 23.Rubio R., Jofré A., Martín B., Aymerich T., & Garriga M. (2014). Characterization of lactic acid bacteria isolated from infant faeces as potential probiotic starter cultures for fermented sausages. Food Microbiology. 2014: 38: 303–311. doi: 10.1016/j.fm.2013.07.015 [DOI] [PubMed] [Google Scholar]
  • 24.Turpin W, Humblot C, Guyot JP. Genetic screening of functional properties of lactic acid bacteria in a fermented pearl millet slurry and in the metagenome of fermented starchy foods. Appl Environ Microbiol.2011; 77(24):8722–34. doi: 10.1128/AEM.05988-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.de Crecy-Lagard V B, El Yacoubi R D de la Garza A, Noiriel, Hanson AD. Comparative genomics of bacterial and plant folate synthesis and salvage: predictions and validations. BMC Genomics.2007; 8:245. doi: 10.1186/1471-2164-8-245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol.1991; 173: 697–703. doi: 10.1128/jb.173.2.697-703.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA. 1977; 74: 5463–7. doi: 10.1073/pnas.74.12.5463 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25: 3389–402. doi: 10.1093/nar/25.17.3389 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Mulaw G, Sisay Tessema T, Muleta D, & Tesfaye A. In Vitro Evaluation of Probiotic Properties of Lactic Acid Bacteria Isolated from Some Traditionally Fermented Ethiopian Food Products. International journal of microbiology.2019; 2019: 7179514. doi: 10.1155/2019/7179514 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gilliland SE, Staley TE, Bush LJ. Importance in bile tolerance of Lactobacillus acidophilus used as a dietary adjunct. J Dairy Sci. 1984; 67: 3045–50. doi: 10.3168/jds.S0022-0302(84)81670-7 [DOI] [PubMed] [Google Scholar]
  • 31.Wayne P (2007) Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing [Google Scholar]
  • 32.Jeong SH, Song W, Bae IK, Kim HS, Kim JS, Park MJ, et al. Broth microdilution methods using B-lactamase inhibitors for the identification of Klebsiella pneumoniae carbapenemases and metallo-beta-lactamases in Gram-negative bacilli. Ann Clin Lab Sci.2014; 44(1): 49–55. [PubMed] [Google Scholar]
  • 33.Bazireh H, Shariati P, Azimzadeh Jamalkandi S, Ahmadi A, & Boroumand MA. Isolation of Novel Probiotic Lactobacillus and Enterococcus Strains From Human Salivary and Fecal Sources. Frontiers in microbiology.2020; 11: 597946. doi: 10.3389/fmicb.2020.597946 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Klejdus B., Petrlova J., Potěšil D., Adam V., Mikelová R., Vacek J., et al. (2004). Simultaneous determination of water- and fat-soluble vitamins in pharmaceutical preparations by high-performance liquid chromatography coupled with diode array detection. Analytica Chimica Acta, 520, 57–67. [Google Scholar]
  • 35.Atef RM, Agha AM, Abdel-Rhaman AA, Nassar NN. The Ying and Yang of Adenosine A1 and A2A Receptors on ERK1/2 Activation in a Rat Model of Global Cerebral Ischemia Reperfusion Injury. Mol Neurobiol. 2018. Feb;55(2):1284–1298. doi: 10.1007/s12035-017-0401-1 Epub 2017 Jan 24. . [DOI] [PubMed] [Google Scholar]
  • 36.Matuszyk A, Ceranowicz P, Warzecha Z, Cieszkowski J, Bonior J, Jaworek J, et al. Obestatin Accelerates the Healing of Acetic Acid-Induced Colitis in Rats. Oxid Med Cell Longev.2016; 2016:2834386. doi: 10.1155/2016/2834386 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cortes-Perez NG, Lefevre F, Corthier G et al. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 2007;25:6581–8. doi: 10.1016/j.vaccine.2007.06.062 [DOI] [PubMed] [Google Scholar]
  • 38.Ballester I, Daddaoua A, López-Posadas R, Nieto A, Suárez MD, Zarzuelo A, et al. The bisphosphonate alendronate improves the damage associated with tri nitro benzene sulfonic acid-induced colitis in rats. Br J Pharmacol.2007; 151(2):206–15. doi: 10.1038/sj.bjp.0707227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Motavallian-Naeini A, Andalib S, Rabbani M, Mahzouni P, Afsharipour M, Minaiyan M. Validation and optimization of experimental colitis induction in rats using 2, 4, 6-trinitrobenzene sulfonic acid. Res Pharm Sci. 2012. 7(3):159–69. [PMC free article] [PubMed] [Google Scholar]
  • 40.Aleisa AM, Al-Rejaie SS, Abuohashish HM, Ola MS, Parmar MY, Ahmed MM. Pretreatment of Gymnema sylvestre revealed the protection against acetic acid-induced ulcerative colitis in rats. BMC Complement Altern Med. 2014; 10:14–49. doi: 10.1186/1472-6882-14-49 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bradford M M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry.1976; 72:248–254. doi: 10.1006/abio.1976.9999 [DOI] [PubMed] [Google Scholar]
  • 42.Nandini K N, Palaksha MN, Mamatha BS, Lekhana AR. Hepatoprotective activity of ethanolic extract of whole plant of gomphrena serrata against hepatotoxicity in rats. Journal of Global Trends in Pharmaceutical Sciences 2020; 11 (1):7371–7381 [Google Scholar]
  • 43.Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione Stransferase activities in rat lung and liver. Biochimica et biophysica acta (BBA)-general subjects. 1979; 582(1):67–78. [DOI] [PubMed] [Google Scholar]
  • 44.Ribeiro M CDO, et al. Evaluation of probiotic properties of Pediococcus acidilactici B14 in association with Lactobacillus acidophilus ATCC 4356 for application in a soy based aerated symbiotic dessert. Braz Arch Biol Technol. 2014; 57: 755–765. [Google Scholar]
  • 45.Bhagat D, Raina N, Kumar A, et al. Probiotic properties of a phytase producing Pediococcus acidilactici strain SMVDUDB2 isolated from traditional fermented cheese product, Kalarei. Sci Rep.2020; 10:1926. doi: 10.1038/s41598-020-58676-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Millette M.; Dupont C.; Archambault D.; Lacroix M. Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates. J. Appl. Microbiol.2006,102, 274–282. [DOI] [PubMed] [Google Scholar]
  • 47.Wang J.; Li L.; Zhao X.; Zhou Z. Partial characteristics and antimicrobial mode of pediocin produced by Pediococcus acidilacticiPA003. Ann. Microbiol.2015,65, 1753–1762 [Google Scholar]
  • 48.Ammor MS, Flórez AB, van Hoek AH, de Los Reyes-Gavilán CG, Aarts HJ, Margolles A, et al. Molecular characterization of intrinsic and acquired antibiotic resistance in lactic acid bacteria and bifidobacteria. J Mol Microbiol Biotechnol. 2008; 14(1–3):6–15. doi: 10.1159/000106077 [DOI] [PubMed] [Google Scholar]
  • 49.Charteris WP, Kelly PM, Morelli L, Collins JK. Gradient diffusion antibiotic susceptibility testing of potentially probiotic lactobacilli. J Food Prot.2001; 64(12):2007–2014. doi: 10.4315/0362-028x-64.12.2007 [DOI] [PubMed] [Google Scholar]
  • 50.Singla V, Mandal S, Sharma P, Anand S, Tomar SK. Antibiotic susceptibility profile of Pediococcus spp. from diverse sources. 3 Biotech. 2018; 8(12):489. doi: 10.1007/s13205-018-1514-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Guan Q, Zhang J. Recent advances: the imbalance of cytokines in the pathogenesis of inflammatory bowel disease. Mediators Inflamm. 2017; 2017:8. doi: 10.1155/2017/4810258 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Nemeth Z H, Bogdanovski D A, Barratt-Stopper P, Paglinco S R, Antonioli L, Rolandelli R H. Crohn’s disease and ulcerative colitis show unique cytokine profiles. Cureus. 2017; 9(4):1177. doi: 10.7759/cureus.1177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Liu M, Zhang X, Hao Y, Ding J, Shen J, Xue Z, et al. Protective effects of a novel probiotic strain: lactococcus lactis ML2018, in colitis: in vivo and in vitro evidence, Food Funct. 2019; 10: 1132–1145. doi: 10.1039/c8fo02301h [DOI] [PubMed] [Google Scholar]
  • 54.Kanmani P, Kim H. Functional capabilities of probiotic strains on attenuation of intestinal epithelial cell inflammatory response induced by TLR4 stimuli, BioFactors. 2019; 45: 223–235. doi: 10.1002/biof.1475 [DOI] [PubMed] [Google Scholar]
  • 55.Vincenzi A, Goettert MI, Volken de Souza CF. An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-α) signaling and gene expression. Cytokine Growth Factor Rev.2021; 57:27–38. doi: 10.1016/j.cytogfr.2020.10.004 [DOI] [PubMed] [Google Scholar]
  • 56.Asadullah K, Sterry W, Volk HD. “Interleukin-10 therapy—review of a new approach,” Pharmacol. Rev. 2003; 55(2): 241–269. doi: 10.1124/pr.55.2.4 [DOI] [PubMed] [Google Scholar]
  • 57.Watanabe A., Yamaguchi T., Murota K., Ishii N., Terao J., Okada S., et al. 2020. Isolation of lactic acid bacteria capable of reducing environmental alkyl and fatty acid hydroperoxides, and the effect of their oral administration on oxidative-stressed nematodes and rats. PloS one, 15(2), e0215113. doi: 10.1371/journal.pone.0215113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.LeBlanc J. G., Levit R., Savoy de Giori G., & de Moreno de LeBlanc A. 2020. Application of vitamin-producing lactic acid bacteria to treat intestinal inflammatory diseases. Applied microbiology and biotechnology, 104(8), 3331–3337. doi: 10.1007/s00253-020-10487-1 [DOI] [PubMed] [Google Scholar]
  • 59.Levit R., de Giori G.S., de Moreno de LeBlanc A. and LeBlanc J.G. 2017. Evaluation of the effect of soymilk fermented by a riboflavin-producing Lactobacillus plantarum strain in a murine model of colitis. Benef Microbes 8, 65–72. doi: 10.3920/BM2016.0063 [DOI] [PubMed] [Google Scholar]
  • 60.Levit R., Savoy de Giori G., de Moreno de LeBlanc A., & LeBlanc J. G. 2020. Recent update on lactic acid bacteria producing riboflavin and folates: application for food fortification and treatment of intestinal inflammation. Journal of applied microbiology, doi: 10.1111/jam.14854 Advance online publication. 10.1111/jam.14854 [DOI] [PubMed] [Google Scholar]
  • 61.National Committee for Clinical Laboratory Standards (NCCLS) (1993) Standard for Antimicrobial Disc Susceptibility Test, Approved Standard NCCLS Publication, Villanova. PA, USA: pp. M2eA5. [Google Scholar]

Decision Letter 0

Mahmoud Abdel Aziz Mabrok

10 Jun 2021

PONE-D-21-15668

Inhibition of Acetic acid-Induced Colitis in Rats by P. acidilactici WNYM (01-03); Vitamin Producers Recovered from  Human Gut Microbiota

PLOS ONE

Dear Dr. Mansour,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 23 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Mahmoud Abdel Aziz Mabrok, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. Please note that in order to use the direct billing option the corresponding author must be affiliated with the chosen institute. Please either amend your manuscript to change the affiliation or corresponding author, or email us at plosone@plos.org with a request to remove this option.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Inhibition of Acetic acid-Induced Colitis in Rats by P. acidilactici WNYM (01-03); Vitamin Producers Recovered from Human Gut Microbiota

The manuscript should be revised for proper used of abbreviations.

Do not start paragraphs with abbreviations or mathematical numbers.

The ethical approval number should be written in details.

Animal handling, anesthesia and euthanasia should be written in details.

How many animals per group?

Why not used one-way ANOVA for statistical analysis to compare among the studied groups.

The pathogenesis of ulcerative colitis in relation to oxidative stress and inflammation should be discussed in more details. The following reference might be helpful:

https://doi.org/10.3109/08923973.2014.998368

The biomedical applications of probiotic should be discussed in more details. The following references might be helpful.

Biomolecules 2021, 11(5), 678; https://doi.org/10.3390/biom11050678

TBARS is a lipid peroxidation marker (not oxidative stress marker). Please discuss.

For oxidative stress markers, why not chose enzymatic antioxidant markers (SOD, CAT or GSH-Px). The authors chose only reduced glutathione (GSH).

I recommend immunohistochemistry of colon tissue (COX-2, Caspase 3, INOS, BCL2, BAX)

Why the authors chose IL10 with TNF-α Why not IL-1beta, IL-6 as proinflammatory cytokines.

Reviewer #2: Major comments:

1- Lack of references in many paragraphs inside the manuscript as follows:

- 2nd paragraph in the Introduction section includes many information without references.

- Last line in page 3 (many studies ??) where are the references of these studies.

2- Methods section also there are many references lacking as follows:

- Acid Tolerance assay ??

- Blood hemolysis

- HPLC for determination of riboflavin & folate

- Determination of oxidative stress biomarkers

3- Expression of the results in the form of tables or figures are necessary & more impressive as text only is not enough as follows:

- Screening the isolation by PCR

- Photo of Gel electrophoresis Band.

- Molecular identification

- HPLC peak point & retention time

4- Gross finding: because you administered the bacterial strains for 14 days before colitis induction, So, this is not treatment regimen, it is prophylactic or preventive strategy. If you administer the strain after colitis induction start, at this case become treatment regimen.

5- Discussion section: there is no discussion for the antibacterial activity of the bacterial strains??

6- Also, the results of antioxidant activity of the bacterial strain are not discussed & no interpretation has mentioned.

Minor corrections:

a- Abbreviation in the title is not preferred (P. Pediococcus)

b- First sentence in the second paragraph in introduction section to be revised.

c- Introduction: 2nd paragraph: Vitamin B lack (un common word) to be changed in to Vitamin B deficiency; Also respiratory contagion to be changed to respiratory infection.

d- Page (4), second paragraph, second sentence is very long need to be revised as not logic to contain (and & furthermore) in the same sentence.

e- Page (10): first paragraph last line, the word after to change to "Later".

f- Result section: isolation of LAB: no need to repeat the first 5 lines as it is mentioned in the method section & the results start definitely from the line 6.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Abdelfattah Mohamed Abdelfattah Ali

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Dear Editor of PLOS ONE.docx

PLoS One. 2021 Jul 26;16(7):e0255092. doi: 10.1371/journal.pone.0255092.r002

Author response to Decision Letter 0


6 Jul 2021

Dear Editor of PLOS ONE,

Dear Reviewers.

Thank you for your valuable comments, which is very helpful

the manuscript has been revised accordingly ( any changes in the text, references, tables, figures are highlighted in green)

Please find my point by point reply on the comments in blue

Reviewer #1:

Inhibition of Acetic acid-Induced Colitis in Rats by P. acidilactici WNYM (01-03); Vitamin Producers Recovered from Human Gut Microbiota

The manuscript should be revised for proper used of abbreviations.Do not start paragraphs with abbreviations or mathematical numbers.

The title Changed to: Inhibition of Acetic acid-Induced Colitis in Rats by New Pediococcus acidilactici Strains, Vitamin Producers Recovered from Human Gut Microbiota

The ethical approval number should be written in details.

The ethical approval number is added

Animal handling, anesthesia and euthanasia should be written in details.

It is added and reference also is added as follows

At the end of the experiment, animals were sacrificed by decapitation under anesthesia by well-trained person using thiopental (50 mg/kg) as demonstrated previously according to AVMA Guidelines for the Euthanasia of Animals: 2020 Edition.

Atef RM, Agha AM, Abdel-Rhaman AA, Nassar NN. The Ying and Yang of Adenosine A1 and A2A Receptors on ERK1/2 Activation in a Rat Model of Global Cerebral Ischemia Reperfusion Injury. Mol Neurobiol. 2018 Feb;55(2):1284-1298. doi: 10.1007/s12035-017-0401-1. Epub 2017 Jan 24. PMID: 28120151.

How many animals per group?

It is already indicated in the method section page 9 as below under the title

Administration of probiotic isolates and induction of colitis

The design of the experiment is presented in Figure (1) where the oral method was used for administration of the selected strains to the experimental rats where the dose contained 109 CFU in volume 200 μL of PBS. The rats were divided into six groups. Each group contained 6 rats:

Why not used one-way ANOVA for statistical analysis to compare among the studied groups.

We changed to ANOVA

The pathogenesis of ulcerative colitis in relation to oxidative stress and inflammation should be discussed in more details. The following reference might be helpful:

https://doi.org/10.3109/08923973.2014.998368

we extend the discussion in this part

The biomedical applications of probiotic should be discussed in more details. The following references might be helpful.

Biomolecules 2021, 11(5), 678; https://doi.org/10.3390/biom11050678

very helpful papers indeed,

TBARS is a lipid peroxidation marker (not oxidative stress marker). Please discuss.

For oxidative stress markers, why not chose enzymatic antioxidant markers (SOD, CAT or GSH-Px). The authors chose only reduced glutathione (GSH).

I recommend immunohistochemistry of colon tissue (COX-2, Caspase 3, INOS, BCL2, BAX)

- We changed the title to Lipid peroxidation within the manuscript

- However; Lipid peroxidation is a sensitive marker due to the high likelihood of lipids to undergo oxidation, and therefore is a highly used oxidative stress marker (Lavie et al. 2004).

- L. Lavie, A. Vishnevsky, P. Lavie Evidence for lipid peroxidation in obstructive sleep apnea Sleep, 27 (2004), pp. 123-128

- Determination of oxidative stress TBARS are produced during lipoperoxidation oxidative stress induced damage of lipids, and are thus a widely used marker of oxidative stress [4,11]

- According to the budget situation, we chose only these markers

- For immunohistochemistry of colon tissue, it is a good recommendation we could work on it in the next paper

- Why the authors chose IL10 with TNF-α Why not IL-1beta, IL-6 as proinflammatory cytokines.

- We concentrated in these two for their importance in addition we have limited budget thus we cannot expand more

Reviewer 2

Dear Editor of PLOS ONE

Please, find the review of the manuscript PONE-D-21-15668 entitled "Inhibition of Acetic acid-Induced Colitis in Rats by P. acidilactici WNYM (01-03); Vitamin Producers Recovered from Human Gut Microbiota"

Major comments:

1- Lack of references in many paragraphs inside the manuscript as follows:

- 2nd paragraph in the Introduction section includes many information without references.

- References are added

- Last line in page 3 (many studies ??) where are the references of these studies.

- References are added

2- Methods section also there are many references lacking as follows:

- Acid Tolerance assay ??

- References is added

- Blood hemolysis

- Reference is added

- HPLC for determination of riboflavin & folate

- Reference is added

- Determination of oxidative stress biomarkers

References are added

3- Expression of the results in the form of tables or figures are necessary & more impressive as text only is not enough as follows:

- Screening the isolation by PCR

- Table 2 was added which show the screening of the isolation by PCR and pH tolerance

- Photo of Gel electrophoresis Band.

- Figure 2 A-B was added to show the gel electrophoresis bands for the three selected isolates

- Molecular identification

- Figure 3 A was added to show the gel electrophoresis bands for the 16Sr RNA amplification fragment from the three isolates

- Figure 3B was added which show the phylogenetic tree for molecular identification

- HPLC peak point & retention time

- Table 3 was added to show the HPLC peak point & retention time

4- Gross finding: because you administered the bacterial strains for 14 days before colitis induction, So, this is not treatment regimen, it is prophylactic or preventive strategy. If you administer the strain after colitis induction start, at this case become treatment regimen.

Actually the bacterial strains were administrated 14 days before colitis induction and 4 days after colitis induction.

The method part has been changed for clarification this point.

5- Discussion section: there is no discussion for the antibacterial activity of the bacterial strains??

The discussion was added for this part

6- Also, the results of antioxidant activity of the bacterial strain are not discussed & no interpretation has mentioned.

The discussion and interpretation was added for this part

Minor corrections:

a- Abbreviation in the title is not preferred (P. Pediococcus)

The title is Changed to:

Inhibition of Acetic acid-Induced Colitis in Rats by New Pediococcus acidilactici Strains, Vitamin Producers Recovered from Human Gut Microbiota

First sentence in the second paragraph in introduction section to be revised.

It is revised to: The vitamins are essential for sustaining the proper functioning of human beings and other organisms.

b- Introduction: 2nd paragraph: Vitamin B lack (un common word) to be changed in to Vitamin B deficiency; Also respiratory contagion to be changed to respiratory infection.

It changed to: Vitamin B deficiency

It changed to: Respiratory infection

c- Page (4), second paragraph, second sentence is very long need to be revised as not logic to contain (and & furthermore) in the same sentence.

It is revised as follows:

WHO/FAO [13] recommends a daily vitamin B9 intake of 400 μg for adults as its deficiency cause megaloblastic anemia [14]; the reduction of the Treg cells which control the immune responses [15]; increased susceptibility to intestinal inflammation [16] and some psychological illnesses [17].

d- Page (10): first paragraph last line, the word after to change to "Later".

The entire sentence is changed to:

Then each group continued its daily dose in the same pattern as before the colitis induction for 4 days and the experiment ended by sacrificing and samples were collected.

e- Result section: isolation of LAB: no need to repeat the first 5 lines as it is mentioned in the method section & the results start definitely from the line 6.

Changed to:

Initially, 150 gram-positive, catalase- negative isolates (data not shown) were selected from the incubation of the fecal samples on MRS agar plates. These isolates were evaluated for their tolerance to high acidity at pH 2.0 and alkaline conditions at pH 9.0. As a result, 49 isolates were picked for further screening according to their tolerance to low pH value by giving 80-85% survival after incubation for 3 hours at pH 2.0 in addition to their tolerance to the high pH value by showing 95 % survival at pH 9.0

Attachment

Submitted filename: PLOS ONE Response to Reviewers..docx

Decision Letter 1

Mahmoud Abdel Aziz Mabrok

12 Jul 2021

Inhibition of Acetic acid-Induced Colitis in Rats by New Pediococcus acidilactici Strains, Vitamin Producers Recovered from Human Gut Microbiota

PONE-D-21-15668R1

Dear Dr. Mansour,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mahmoud Abdel Aziz Mabrok, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Based on the reviewers' comment, I would like to appreciate your efforts to present the manuscript in the current version. The authors addressed all scientific comments and inquiries as required, and therefore the final decision is acceptable. However, based on my review, I would like to suggest adding a small paragraph on MDR (multi-drug resistance and its negative impact on the animal industry, which also reflects the potential use of certain probiotics as an alternative compound for disease prevention and control. Please use the following valuable manuscripts as a guide for further editing. They discussed briefly the emergence of MDR in different animals, including poultry, cattles, fish

1-PMID: 32235800

2- PMID: 32497922

3-PMID: 32472209 DOI: 10.1186/s13568-020-01037-z

4-PMID: 33061472

5- https://doi.org/10.1016/j.aquaculture.2020.736070

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: As The authors addressed the reviewers comments, I suggest acceptance of the manuscript. The manuscript is acceptable in the current form.

Reviewer #2: No more comments as the manuscript has been revised correctly, language is carefully written clear & correct; No topographical errors present and no specific errors

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Abdelfattah Mohamed Abdelfattah Ali

Acceptance letter

Mahmoud Abdel Aziz Mabrok

16 Jul 2021

PONE-D-21-15668R1

Inhibition of Acetic acid-Induced Colitis in Rats by New Pediococcus acidilactici Strains, Vitamin Producers Recovered from Human Gut Microbiota

Dear Dr. Mansour:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Mahmoud Abdel Aziz Mabrok

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. The antibiotics susceptibility of the isolates; WNYM01, WNYM02 and WNYM03.

    (DOCX)

    S2 Table. Assessment of inflammatory markers in the cytoplasmic extracts from homogenate rat’s intestinal tissues tumor necrosis factor-α (TNF-α) and intelukin-10 (IL-10).

    The rat experimental groups: control, received PBS only; Ulcerative, received PBS and colitis induction; A, received WNYM01 + colitis induction; B, received WNYM02 + colitis induction; C, received WNYM03 + colitis induction. M, received Mixture of WNYM (01–03) + colitis induction. Data are presented as mean ± S.D. (n = 3). *Significance compared to Ulcerative. Mean differences are significant (p < 0.05).

    (DOCX)

    S3 Table. Assessment the levels of lipid peroxidation marker thiobarbituric acid reactive substances (TBARS) and oxidative stress biomarkers glutathione (GSH) in the cytoplasmic extracts from homogenate rat’s intestinal tissues.

    The rat experimental groups: control, received PBS only; Ulcerative, received PBS and colitis induction; A, received WNYM01 + colitis induction; B, received WNYM02 + colitis induction; C, received WNYM03 + colitis induction. M, received Mixture of WNYM (01–03) + colitis induction. Data are presented as mean ± S.D. (n = 3). * Significance compared to Ulcerative. Mean differences are significant (p < 0.05).

    (DOCX)

    Attachment

    Submitted filename: Dear Editor of PLOS ONE.docx

    Attachment

    Submitted filename: PLOS ONE Response to Reviewers..docx

    Data Availability Statement

    All relevant data are within the paper, its Supporting Information files and GenBank under the accession numbers MW856830, MW856831 and MW865736.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES